Study shows that severe COVID-19 elevates the long-term risk of major adverse cardiac events (MACE), making it comparable to coronary artery disease. It also highlights a genetic interaction with ABO blood type, influencing cardiovascular outcomes.
Phase III study halted: Ferrer’s oral edaravone disappoints in ALS – Pharmaceutical Technology
Share this article The high failure rate in ALS clinical trials is often attributed to the disease’s unclear aetiology and complex pathophysiology. Credit: ANDREI ASKIRKA
January 31, 2024